HIV treatment pause after stem cell transplant
Part of Infections clinical trials.
This trial tests if a person with HIV who received a stem cell transplant from a donor with a special genetic mutation (CCR5 delta32) can safely stop their HIV medications. It aims to see if the transplant has cured the HIV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must have a positive HIV test
- Must have already had a stem cell transplant from a donor with the CCR5 delta32 mutation
- Must be 18 years or older
- Must be willing to follow the study rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if two drugs, baricitinib and sirolimus, can help control HIV after stopping standard antiretroviral therapy (ART). It aims to see if these immune treatments allow patients to maintain viral suppression without daily pills.
This study looks at whether some people with HIV can keep the virus controlled even if they temporarily stop HIV medicines (an “analytic treatment interruption”). If you qualify, it may help researchers learn what it would take for an HIV cure.
This study looks at a planned, supervised “treatment interruption” period for people with HIV who are very well controlled on HIV medicines. It mainly aims to understand what happens when therapy is paused and how to reduce the risk of passing HIV to others.
This trial tests whether it's safe to stop one type of anti-rejection medication (tacrolimus) earlier than usual after a stem cell transplant from a matched donor. If you qualify, you may be able to reduce your long-term medication burden.
This Phase 2 study uses special scans (PET/CT) and tissue sampling (biopsy) to learn what is happening in the body while people with HIV take a planned break from antiretroviral therapy (ART) for up to 90 days. It may help researchers find better ways to control HIV without ongoing treatment, though joining involves careful monitoring during the pause.
This study looks at what happens when HIV treatment (ART) is intentionally paused in people who are already enrolled in a specific research study (RV254) and recently joined a protocol that included an earlier treatment pause. It may help researchers understand safety and how to manage treatment changes, but it has strict participation and consent requirements.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.